Cadrenal Therapeutics Receives Clear FDA Guidance for Pivotal Phase 3 Trial of CAD-1005 in HIT
CVKD sits 68% above its 52-week low of $4.21.
Summary
Cadrenal Therapeutics announced receipt of official FDA End-of-Phase 2 meeting minutes, providing clear guidance for advancing its lead drug candidate, CAD-1005, directly into a pivotal Phase 3 trial for heparin-induced thrombocytopenia (HIT).
Key Events · Product Development and Regulatory · CVKD
-
FDA Guidance for Pivotal Phase 3 Trial
Cadrenal Therapeutics received official FDA End-of-Phase 2 meeting minutes, providing clear guidance on the protocol design, study population, dosing, and primary endpoint for the pivotal Phase 3 registration trial of CAD-1005 in heparin-induced thrombocytopenia (HIT).
-
Direct Advancement to Phase 3
The company plans to advance directly to a randomized, blinded, placebo-controlled Phase 3 study evaluating CAD-1005 in approximately 120 patients worldwide, with a projected NDA submission in 2029. This follows positive Phase 2 data showing a significant reduction in thrombotic events.
-
Q1 Financials and Recent Financing
Cadrenal reported a net loss of $2.5 million for Q1 2026 and held $2.3 million in cash and cash equivalents as of March 31, 2026. Subsequent to quarter-end, the company completed a $2.5 million financing on April 1, 2026, to support near-term development activities.
Analysis · CVKD · Life Sciences
This 8-K provides crucial clarity on the development path for Cadrenal's lead asset, CAD-1005, following the End-of-Phase 2 meeting with the FDA. Receiving official minutes and detailed guidance for a pivotal Phase 3 trial significantly de-risks the program and outlines a clear path towards a projected NDA submission in 2029. This positive development for their lead drug candidate, which targets a life-threatening condition, is a strong signal for the company's long-term prospects. While the company's financial position remains challenging, as highlighted in the concurrently filed 10-Q, the $2.5 million financing provides some near-term liquidity. Investors should monitor the initiation and progress of the Phase 3 trial and future financing activities.
At the time of this filing, CVKD was trading at $7.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19M. The 52-week trading range was $4.21 to $16.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.